×
About 5 results

ALLMedicine™ Anklyosing Spondylitis Center

Research & Reviews  1 results

Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.
https://doi.org/10.1016/j.rdc.2012.08.004
Rheumatic Diseases Clinics of North America; Song IH, Maksymowych WP

Oct 23rd, 2012 - Tumor necrosis factor α inhibitors (TNF blockers) have revolutionized the treatment of patients with anklyosing spondylitis. Despite clinical efficacy, there are questions and controversies treating rheumatologists face, which this review discusse...

see more →

News  1 results

Oral JAK Inhibitor Promising in Ankylosing Spondylitis
https://www.medscape.com/viewarticle/864608

Jun 9th, 2016 - LONDON, United Kingdom — The oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz, Pfizer) might be a new option for patients with ankylosing spondylitis, according to results from a new phase 2 study. "This is the first study to demonstrate the...

see more →